Four-day cyclic rats fed 7,12-dimethylbenz(a)anthracene (DMBA) (20 mg) at 50 days of age had peak prolactin, oestradiol and uterine wet weights at pro-oestrus. Tamoxifen (50, 200 and 800 \ g=m\ gdaily), administered to ovariectomized rats, produced significant (P < 0\m=.\05) decreases in oestrogen-stimulated prolactin levels but was unable to reduce prolactin to control values. Tamoxifen (12\m=.\5, 50 and 200\g=m\gdaily) produced decreases in size in DMBAinduced rat mammary carcinomata in intact rats although some tumours did not respond to therapy. The ability of the pituitary to produce prolactin was not impaired. Decreases in uterine wet weights and peripheral oestradiol levels occurred during tamoxifen treatment.
INTRODUCTION
Prolactin has been shown to be intimately involved in the growth of dimethylbenz(a)-anthracene (DMBA)-induced rat mammary carcinomata (Pearson, Molina, Butler, Llerena & Nasr, 1972) , although the recent work by Sinha, Cooper & Dao (1973) suggests that simul¬ taneous oestrogen stimulation is also required for effective tumour growth. Since oestrogens are known to raise plasma prolactin levels (Grosvenor & Turner, 1960; Chen & Meites, 1970) , non-steroidal anti-oestrogens may exert an anti-tumour effect by impairing oestrogenstimulated prolactin release. In the rat, U-11,100A (nafoxidine; l-[2-[/>-(3,4-dihydro-6-methoxy-2-phenyl-l-naphthyl)-phenoxy]ethyl]-pyrrolidine) (Heuson, Waelbroeck, Legros, Gallez, Robyn & L'Hermite, 1971/72) , MER 25 (ethamoxytriphetol, l-(/?-/ff-diethylaminoethoxyphenyl)-2-(/;-methoxyphenyl) ethanol) and ICI 46,474 (tamoxifen, trans l-(p-ß-dimethylaminoethoxyphenyl)-l,2-diphenyl but-1-ene) (Jordan, Koerner & Robison, 1975) significantly reduce oestrogen-raised levels of prolactin, thereby suggesting a possible role in anti-tumour activity. Although the DMBA-induced tumour model gives rise to many types of tumours with varying hormonal responses (Mobbs, 1966;  Leung, Sasaki & Leung, 1975) , this similarity to human breast cancer was considered ideal to determine whether the inhibition of oestrogen-stimulated prolactin release paralleled the anti-oestrogenic and anti-tumour properties of tamoxifen. (iii) Anti-tumour activity of tamoxifen Tumours were induced in thirty 50-day-old Sprague-Dawley rats as previously described (Jordan & Dowse, 1976 (Jordan & Dowse, 1976) . Results were calculated as percentage increase or decrease of the tumour area recorded before treatment. Only tumours present at the start of the experiment were followed, although the occurrence of other tumours in the groups was noted. At the termination of the blind experiment vaginal smears were recorded for a further 3 days and the plasma and uteri were obtained at 11.00-12.00 h on day 3, as described in (/') above. pooled extract evaporated to dryness. Samples were dissolved in iso-octane, chromato¬ graphed on Celite columns and assayed using the methods presented by Labhsetwar & Watson (1974) . Assay sensitivity was 5 pg. Recoveries were in the range 80-85 %. Results were corrected for 100 % recovery by the addition of [3H]oestradiol to plasma before extraction.
Prolactin
Plasma was assayed using the methods described by Odell, Rayford & Ross (1967) . Rat prolactin and antibody were obtained from the NIAMDD. Results are expressed as ng NIAMDD-rat prolactin-RPl standard/ml rat plasma. Sensitivity was 0-25 ng/ml.
RESULTS

Levels of oestradiol and prolactin during the oestrous cycle
The results are summarized in Table 1 . Uterine wet weight, oestradiol and prolactin levels were all maximal at pro-oestrus.
Inhibition of oestrogen-stimulated prolactin release
The administration of oestradiol (5/¿g/day, s.c, in 0-1 ml peanut oil for 8 days) to 7-day ovariectomized rats produced a sharp increase in uterine weight and plasma prolactin levels (Table 2) . A progressive decrease in uterine wet weight was observed with increasing doses of tamoxifen (12.5, 50, 200 and 800/¿g/day) but although significant (P < 0-05) decreases in prolactin levels were noted this effect plateaued above 50 /¿g/day and the levels were not reduced to those found in ovariectomized rats. In a parallel experiment tamoxifen alone was administered to ovariectomized rats. Administration of 800 /¿g tamoxifen/day produced significant (P < 005) increases in uterine wet weight although no significant rise was observed in the level of plasma prolactin. Anti-tumour activity of tamoxifen Tamoxifen was administered on a blind basis at three dose levels (12-5, 50 and 200 /¿g/day) to rats with established DMBA-induced rat mammary carcinomata. The percentage change in tumour areas for the three treated groups and the vehicle-treated controls is presented in Fig. 1 Shaikh (1971) demonstrated peak production of ovarian oestradiol at 12.00 h during prooestrus with a rapid decrease by 12-00 h at oestrus. In the present study peripheral oestradiol was found to be maximal during pro-oestrus (Table 1) with a significant decrease in levels in the circulation during oestrus and metoestrus. The increased levels of oestradiol result in rapid increases in uterine wet weight (Astwood, 1938) and peripheral prolactin levels (Chen & Meites, 1970) . Pro-oestrous rises in prolactin have previously been noted by other workers (Kwa & Verhofstad, 1967; Niswender, Chen, Midgley, Meites & Ellis, 1969; Pearson et al. 1972 ). Clearly, after DMBA administration, fluctuations in oestradiol, pro¬ lactin and uterine wet weights occur consistent with stages of the oestrous cycle, as deter¬ mined from vaginal smears.
Although tamoxifen significantly (P < 0-05) reduced the oestrogen-stimulated rise in plasma prolactin levels (Table 2) , there was a more profound effect upon oestrogenstimulated rises in uterine weight ( < 0001). We have previously reported this lack of parallelism in the ability of tamoxifen to inhibit oestrogen-stimulated events (Jordan et al. 1975) . A similar anti-oestrogenic compound, U-11,100A, was reported by Heuson et al. (1971/72) to inhibit oestrogen-stimulated rises in serum prolactin, but again these workers were unable to reduce the prolactin levels to those found in the ovariectomized rat.
The inability to demonstrate a dose-response relationship with tamoxifen for anti-tumour effects (Fig. 1) probably reflect the heterogeneous DMBA-induced tumour populations, since each dose was previously shown to be increasingly anti-uterotrophic (Table 2) . Leung et al. (1975) have reported that DMBA-induced tumours in the ovariectomized rat may respond to either oestradiol or prolactin but the non-steroid anti-oestrogen, U-l , was unable to control the prolactin-dependent tumours. Although the majority of tumour areas decreased during tamoxifen therapy, the ability of the pituitary to continue to produce high levels of prolactin in the circulation suggests that prolactin-dependent tumours, which may be insensitive to anti-oestrogen therapy, continue to survive by activa¬ tion of the prolactin receptor (Turkington, 1974) . The possibility that insensitive tumours in the various treatment groups had attained hormone independence cannot be excluded.
Although the study did not demonstrate a clear decrease in oestradiol levels in the circula¬ tion during tamoxifen therapy (Table 3 ) the 50 and 200 /¿g treated groups were only half of the control pro-oestrous levels. In a recent study (Watson, Alain, Anderson & Heald, 1974) , tamoxifen (200 /¿g/kg) was found to inhibit the oestrogen surge before implantation. This effect was thought to be a direct effect upon the ovary since levels of luteinizing hormone in the circulation were unchanged. If in fact oestrogen levels are reduced, either by direct action on the ovary or by reduction in follicle-stimulating hormone levels, then this would enhance the effectiveness of the competitive antagonism at the oestrogen receptor by tamoxifen (Skidmore, Walpole & Woodburn, 1972) , and thus the direct effect of oestrogens at the tumour level would be further retarded (Lee & Oyasu, 1974) .
In conclusion, tamoxifen was found partially to reduce oestrogen-stimulated prolactin levels in the ovariectomized rat, but although tamoxifen inhibited the growth of DMBAinduced rat mammary carcinomata, the ability of the pituitary to produce prolactin was not mpaired. Therefore, tamoxifen may have a direct effect upon the tumour by blocking oestrogen binding (Jordan & Dowse, 1976) rather than an indirect action by completely blocking oestrogen-stimulated prolactin release.
